Table 1.

Summary of Hypertensive Therapy Studies in AD.

Reference	Study Setting	Participants and Follow-Up	Treatment	Main Result
232	SHEP	4736 people, ~72 years at baseline, followed up to 4.5 years	Diuretic ± β-blocker ± hypertensive drug or placebo	No significant effect of treatment on AD risk
233, 234	MRC trial	2584 people, ~69 years at baseline, followed up to 3.9 years	Diuretic or β-blocker or placebo	No significant effect of treatment on AD risk
235, 236	SCOPE	4964 people, ~76 years at baseline, followed up to 4.5 years	ATI receptor agonist or placebo (candesartan ± hydrochlorothiazide versus placebo)	Significantly less cognitive decline in the treated group
237	PROGRESS	6105 people, ~64 years at baseline, followed up to 4.5 years	ACE inhibitor ± diuretic or placebo (perindopril ± indapamide versus placebo)	Decreased the rates of dementia in actively treated patients
238–240	Syst-Eur study	2418 people, ~68 years at baseline, followed up to 2 years	Calcium channel blocker ± ACE inhibitor ± diuretic or placebo (nitrendipine ± enalapril ± hydrochlorothiazide versus placebo	Decreased the risk of dementia by 55%

NOTE: This table is a summary of randomized, double-blind, placebo-controlled studies describing the association between hypertension and antihypertensive therapy in relation to AD and has been adapted from Takeda et al.¹ and Poon.²⁴¹

Abbreviations: ACE, angiotensin converting enzyme; AD, Alzheimer's disease; ATI, angiotensin II type 1; MRC, Medical Research Council; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe.